Black Diamond Therapeutics reports silevertinib's 60% ORR in NSCLC patients.

Black Diamond Therapeutics reports silevertinib's robust anti-tumor activity in 43 1L NSCLC patients with 35 different non-classical EGFR mutations, with an ORR of 60% and a CNS response rate of 86%. No new safety signals have been observed to date. PFS data for 1L NSCLC patients is expected in Q2 2026. The company plans to initiate a randomized Phase 2 trial of silevertinib in newly diagnosed GBM patients in 1H 2026.